Introduction
============

Cervical cancer, the most common gynecological malignant disorder worldwide, remains as the major cause of cancer related mortality among women in the developing countries.[@b1-ott-7-2161],[@b2-ott-7-2161] Radiotherapy with or without cisplatin based chemotherapy has been the primary treatment of choice on locally advanced stage cervical carcinoma, though this is only effective with low-resistance cells. Tumor response and survival rates are highly variable among individuals with different tumor radiosensitivities. Tumor radiosensitivity is regulated by several factors, such as DNA repair mechanisms, cell cycle distribution, and genetic instability, yet none of these parameters is predictive of tumor sensitivity in vivo.[@b3-ott-7-2161],[@b4-ott-7-2161]

Carcinogenesis in cancer of the cervix is predominantly the result of activities of the human papillomavirus (HPV) oncogenes *E6* and *E7*, which disturb the regulation of cell cycle and apoptotic pathways, especially via intervention in p53 and Rb pathways, respectively.[@b5-ott-7-2161],[@b6-ott-7-2161] Even though the main action mechanism of E6 is its interference with p53 function, there are also reports of p53-independent actions.[@b6-ott-7-2161] It has also been hypothesized that p73 may play a role in inducing apoptosis and cell cycle arrest in response to radiation, in a p53-independent manner, by having a compensatory role in p53 dysfunction via triggering p53-independent apoptosis or cell cycle effectors in cancer cells.[@b7-ott-7-2161]

Regarding apoptotic pathways, B-cell lymphoma 2 (Bcl-2) family proteins have been of special importance within the large family of apoptosis-related proteins, including anti-apoptotic prosurvival proteins (such as Bcl-2 and B-cell lymphoma-extra-large \[Bcl-xL\]) and pro-apoptotic proteins (such as BH3-only proteins, BCL-2-antagonist/killer \[Bak\] and BCL-2-associated X protein \[Bax\]), as they form crossroads for both extrinsic and intrinsic pathways.[@b8-ott-7-2161] It has been considered that the effect of anticancer treatment-induced apoptosis may be regulated by the balance between pro- and anti-apoptotic ratio of mitochondrial proteins, such as Bcl-2, Bcl-xL, Bak or Bax.[@b9-ott-7-2161] Studies on the therapeutic effects of p53 or Bcl-2 family are inconsistent, yet the role of Bcl-2 as a prognostic factor is more established.[@b10-ott-7-2161],[@b11-ott-7-2161]

One of the novel anti-apoptotic proteins with prognostic potential has been SAG/ROC/Rbx/Hrt (sensitive to apoptosis gene/regulators of cullins/RING box protein). SAG is a member of RING finger family and its expression is induced by mitogenic stimulation.[@b12-ott-7-2161] It has been proposed that SAG might be an attractive target for anticancer therapy and a valuable factor in discerning the prognosis of the disease[@b13-ott-7-2161],[@b14-ott-7-2161] given its well-documented radiosensitizing property and likely role as a protective agent against apoptosis induced by ionizing-radiation.[@b15-ott-7-2161]

The possible involvement of cell cycle, DNA repair, and apoptotic genes in the progress of cancer is still of special interest. Therefore, the present study focuses on the potential effects of anti-apoptotic protein (SAG), mitochondrial apoptotic proteins (Bcl-xL and Bak), and tumor suppressor proteins (p73 and p53) in response to radio/chemotherapy in relation to clinical parameters and survival in patients with cervical carcinoma over a follow-up period of 5 to 8 years.

Materials and methods
=====================

Study population
----------------

A total of 20 patients with clinically advanced staged carcinoma of the cervix (International Federation of Gynecology and Obstetrics \[FIGO\] stage IIB-IVA) aged 40 to 75 years and 20 patients with prior gynecological operations due to causes other than cancer were included in this study. The expression profile of anti-apoptotic protein SAG, mitochondrial apoptotic proteins Bcl-xL and Bak, and tumor suppressor proteins p73 and p53 were examined in real-time polymerase chain reaction (PCR) experiments in terms of their relation to clinical parameters and survival during the follow-up period.

Tissue samples were collected from patients after the receipt of formal ethical approval from the appropriate ethical committees related to the Marmara University School of Medicine. All patients provided written informed consent before undergoing diagnostic cervical biopsy. The median follow-up time for surviving patients was 60 months. The clinicopathological features and survival times of all the patients are presented in [Table 1](#t1-ott-7-2161){ref-type="table"}.

Therapy
-------

The study subjects with histologically proven squamous cell carcinoma of the uterine cervix were treated using definitive radiotherapy with concomitant cisplatin on a weekly basis in the Radiation Oncology Department of Kartal Education and Research Hospital. Pretreatment staging and evaluation included a history, a physical and gynecological examination (under anesthesia if necessary), routine blood counts, kidney function tests, chest X-rays, and total abdominal computed tomography (CT) or magnetic resonance imaging (MRI). Patients were staged jointly by radiation and gynecologic oncologists according to the FIGO classification.

Patients were treated with a combination of external beam radiation therapy and high-dose-rate remote control after-loading intra-cavitary radiation therapy. External pelvic irradiation was administered with 15 MV photons or cobalt-60 gamma rays at a dose of 2 Gy per fraction, five fractions per week, for a total dose of 50. The intra-cavitary radiation therapy was administered with high-dose-rate Curietron Cesium-137 sources. A total dose of 20 Gy was delivered as brachytherapy at point A in three fractions. A short infusion of cisplatin (40 mg/m^2^, once per week) was applied concomitantly during external radiotherapy.

Follow-up
---------

The follow-up period was defined as the time interval between the surgery and last medical appointment or death, and involved a 5 to 8-year period. Regular follow-up consisted of physical examinations, with 3-month intervals during the first 2 years, and 6-month intervals thereafter. Patients in whom signs of metastatic disease were present underwent further investigations. Disease relapse was defined as either local recurrence or the development of metastasis, and was determined through clinical and radiographic studies using CTs or MRIs, or by tissue biopsy, invariably. Local-free survival time (months), disease-free survival time (months) and overall survival (OS) time (months) were evaluated, and the patients' statuses were followed until December 2012.

Real-time PCR
-------------

Total ribonucleic acid (RNA) was extracted from biopsies of 20--30 mg of cervical tumor or normal cervical tissue samples and then stored in RNAlater solution until the day of experiment (for up to 4 weeks). Total RNA was purified using the RNeasy Mini Kit (Qiagen NV, Venlo, the Netherlands) according to the manufacturer's instructions. Samples were treated on column with DNase I (Qiagen) to remove any possible contaminating genomic DNA. RNA samples were quantified by optical density measurements and their purity was assessed using agarose gel electrophoresis and PCR amplifications. One microgram of total RNA was reverse transcribed using the Transcriptor High Fidelity cDNA Synthesis kit (Hoffman-La Roche Ltd, Basel, Switzerland) according to the manufacturer's guidelines. cDNA's were diluted ten times and used as a template in real-time PCR reactions. Real-time PCR was applied using the LightCycler 480 instrument and LightCycler 480 SYBR Green I Master kit (Hoffman-La Roche Ltd). SAG expression was analyzed using the following primers: forward (5′-CGG GAT CCA TGG CCG ACG TGG AAG-3′) and reverse (5′-CGA AGC TTT CAT TTG CCG ATT CTT TGG AC-3′). The expressions of other apoptotic pathway genes (Bcl-xL, Bak, p53 and p73) were analyzed using the following primers: Bcl-xL forward (5′-CCA GAA GGG ACT GAA TCG-3′) and reverse (5′-CCT TGT CTA CGC TTT CCA C-3′); Bak forward (5′-GAC CCA GAG ATG GTC ACC TT-3′) and reverse (5′-TCA TAG CGT CGG TTG ATG T-3′); p53 forward (5′-AGG CCT AAC TCA AGG AT-3′) and reverse (5′-CCC TTT TTG GAC TTC AGG TG-3′); p73 forward (5′-GCT CGG GAG GGA CTT CAA -3′) and reverse (5′-CTC ATA GGG CAC CAC GAC -3′). β-actin gene expression was used in parallel reactions as an internal PCR control. The primer sequences for the house-keeping gene β-actin were β-act forward (5′-CCA ACC GCG AGA AGA TGA-3′) and β-act reverse (5′-CCA GAG GCG TAC AGG GAT AG-3′). Relative expression levels were determined using the Pfaffl method, where delta C~t~ values were calculated for genes of interest between tumor and normal tissues and normalized relative to the changes in the house-keeping gene β-actin. Tumor and normal tissues were paired according to the closest age.

Statistical analysis
--------------------

Statistical analysis was performed using MedCalc Statistical Software version 12.7.7 (MedCalc Software bvba, Ostend, Belgium; <http://www.medcalc.org>; 2013). Chi-square test was used for the comparison of categorical data, while Spearman's correlation analysis was used to analyze correlations between gene expressions. The Breslow test was used to determine the relation between gene expressions and survival via univariate analysis. Survival analysis was performed using Kaplan--Meier analysis and comparisons were made using the log-rank test. Correlates of survival were determined via Cox-regression analysis. Data were expressed as mean ± standard deviation (SD), minimum-maximum (min-max), percent (%) and 95% confidence interval (CI) where appropriate. *P*\<0.05 was considered statistically significant.

Results
=======

Gene expression according to patient age and tumor characteristics
------------------------------------------------------------------

Ratio of fold changes in gene expression relative to the house-keeping gene were evaluated, with expressions classified as "high" when below the median value, or "low" when the reverse was true. The median values for fold changes in each group were determined as 0.053, 3.873, 2.813, 0.047, 2.882 for SAG, Bcl-xL, Bak, p53 and p73 expressions, respectively.

No significant differences were noted in the high, low, or overall expression of the SAG, Bcl-xL, Bak, p73 and p53 genes with respect to age (≤50 versus \[vs\] \>51 years), stage of tumor (IIB vs IIIB-IVA), and grade of tumor (poor vs moderate-well) ([Table 2](#t2-ott-7-2161){ref-type="table"}).

Correlation between gene expressions
------------------------------------

A significant positive correlation was noted between the SAG and Bcl-xL genes (*r*=0.752, *P*\<0.001) and between the SAG and Bak genes (*r*=0.589, *P*=0.006). The Spearman correlation test also revealed a close link between two well known, oppositely working pro- and anti-apoptotic proteins: Bcl-xL and Bak from the Bcl-2 family (*r*=0.550, *P*=0.012), and two tumor suppressors, p53 and p73, of the same family (*r*=0.562, *P*=0.010), as expected ([Table 3](#t3-ott-7-2161){ref-type="table"}).

Relationship between gene expression and survival
-------------------------------------------------

Median (min-max) OS was significantly longer in lower expression of SAG (89.3 (22.7--91.7) vs 46.4 (4.5--89.1) months, *P*=0.026), Bcl-xL (89.1 (47.5--91.7) vs 45.1 (4.5--87.4) months, *P*=0.002) and p53 (86.3 (22.7--91.7) vs 45.3 (4.5--89.4) months, *P*=0.027) when compared to higher expressions of each gene ([Figure 1](#f1-ott-7-2161){ref-type="fig"} and [Table 4](#t4-ott-7-2161){ref-type="table"}).

No significant association was noted between the Bak and p73 gene expressions and OS, and no gene expressions were associated with local-recurrence free survival (months) and disease-free survival (months) ([Table 4](#t4-ott-7-2161){ref-type="table"}).

The Kaplan--Meier survival curves of the log-rank analysis data showed that low OS expression levels might well be related to high SAG (*P*=0.026), Bcl-xL (*P*=0.002), and p53 (*P*=0.027) expression levels ([Figure 2](#f2-ott-7-2161){ref-type="fig"}).

Multivariate analysis for genes as predictive factors of OS
-----------------------------------------------------------

Among the genes determined to be significantly associated with OS in the univariate analysis (SAG, Bcl-xL, and p53), only p53 was identified as a significant predictor of OS in the multivariate analysis, with an 8.53-fold increase in the OS in low over high expression of the p53 gene (hazard ratio, 8.53, 95% CI: 1.34--54.2, *P*=0.023) ([Table 5](#t5-ott-7-2161){ref-type="table"}).

Discussion
==========

Our findings revealed that while no significant differences were noted in the expression profiles of the apoptotic pathway proteins with respect to age (≤50 vs \>51 years), stage (IIB vs IIIB--IVA), and grade of tumor (poor vs moderate-well), a significant positive correlation was noted between the SAG/Bcl-xL, SAG/Bak, Bcl-xL/Bak, and p53/p73 genes. Low expression of SAG, Bcl-xL, and p53 proteins was associated with a significantly longer OS duration in the univariate analysis, whereas only p53 was confirmed to be a significant predictor of OS in the multivariate analysis, with an 8.53-fold increase in OS in low over high expression of the p53 gene.

In a previous study, our group investigated the prognostic role of SAG in advanced stage rectal cancers and found a significant correlation between expression levels and OS time.[@b16-ott-7-2161] In this study, we have demonstrated that SAG has a similar outcome in cases of cervical carcinoma, which is a different type of cancer with a virus-based origin.

Neither local-recurrence free survival nor disease-free survival was associated with the expression of the apoptotic pathway proteins. In the univariate analysis, expressions of anti-apoptotic protein SAG, mitochondrial apoptotic protein Bcl-xL, and tumor suppressor protein p53 were found to be closely related to OS rate, along with significant correlation between SAG and Bcl-xL genes, while the expression of p53 appeared to be a strong candidate to estimate prognosis of cervical cancer, based on multivariate analysis.

p53 is a well-known tumor suppressor protein that can mobilize two competing pathways, cell cycle arrest or cell death, depending on the cytotoxic effect, status of the cell cycle, repair mechanisms, and checkpoints. Prevention of cell cycle arrest by blocking the related genes such as p53 can cause abrogation of repair mechanisms and may eventually lead to cell death. Numerous studies have pointed out that p53 may regulate mitochondrial Bcl-2 family members, both pro- and anti-apoptotic, such as Bak, Bax, Bcl-xL[@b17-ott-7-2161],[@b18-ott-7-2161] and that p53 can directly initiate the translocalization of proapoptotic members to mitochondria and activates them to trigger mitochondrial leakage.[@b1-ott-7-2161] p53 function, on the other hand, is regulated by post-translational modifications such as phosphorylation, acetylation, and ubiquitination. Ubiquitin-mediated degradation of p53 promoted by E6 causes reduced p53 activity in HPV-infected cervical carcinoma, and a compensatory role has been proposed for p73 regarding this issue.[@b6-ott-7-2161]

While the pairwise comparison of expression levels showed a significant correlation between the Bak and p73 genes, the results as to the effect of these proteins in prognosis were far from significant in all analyses, likely due to the fact that the proteins' joint effects of expression and action could not be acquired in such a small study size (data not shown).

Our findings accord with the data of other studies that have indicated p53 as a predictor of prognosis in association with OS.[@b19-ott-7-2161]--[@b21-ott-7-2161] The role of p73, on the other hand, is highly questionable and complex. Although a significant association between the overexpression of p73 and cellular sensitivity in cervical cancers after radiotherapy has been reported by Liu et al,[@b7-ott-7-2161] no correlation was observed between HPV infections and p73 expressions in the study. Furthermore, the p73 gene produces various isoforms, and recent reports indicate that the balance between its two main isoforms, an NH~2~-terminal truncated form of p73 (ΔNp73) and full-length wild-type TA isoform of p73 (TAp73α), may be influential in clinical outcomes.[@b22-ott-7-2161],[@b23-ott-7-2161] While no correlation was found in the present study between wild-type p73 expression and survival, this could be due to the lack of isoform analyses in the study. Though the levels of expression did not differ significantly with respect to the stage and grade of cervical carcinoma, the expressions of the SAG, Bcl-xL, and p53 proteins displayed longer OS times in our study population. The proposed co-regulatory role of p73, however, could not be verified, as OS and disease-free survival results were very close in terms of both the high and low expression groups. We cannot affirm whether this absence of correlation is due to the counter effects of different isoforms or the study's small sample size as our results were far from significant.

Conclusion
==========

In conclusion, our findings revealed no association between the apoptotic pathway proteins of study and the clinicopathological characteristics of patients with cervical carcinoma, while a reverse correlation was found to exist for the SAG, Bcl-xL, and p53 expressions in relation to the longer life-spans of patients. Especially low p53 expression appears to be useful as a prognostic predictor in patients with cervical carcinoma. The positive effect of low SAG expression on survival should further be confirmed by studies with larger cohorts. Even though the origins and applied therapies for cervical cancer are straightforward, the molecular regulatory mechanisms and apoptotic routes related to tumorigenesis require further study to establish improved personalized approaches to such therapy.
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![Comparison of survival up to 8 years follow-up in terms of the study's different parameters.\
**Note:** Expressions were normalized with respect to the house-keeping control and assignments were made relative to their median values.\
**Abbreviations:** SAG, sensitive to apoptosis gene; Bcl-xL, B-cell lymphoma-extra-large; Bak, Bcl-2 homologous antagonist/killer.](ott-7-2161Fig1){#f1-ott-7-2161}

![Kaplan--Meier survival curves with univariate log-rank comparisons at the end of 8 years.\
**Note:** (**A**) Sensitive to apoptosis (SAG); (**B**) B-cell lymphoma-extra large (Bcl-xL); (**C**) p53.\
**Abbreviations:** Cum, cumulative; t, time; mo, months.](ott-7-2161Fig2){#f2-ott-7-2161}

###### 

Clinicopathological features and respective survival times of 20 patients with cervical carcinoma

  Patient number   Age   Stage   Histological type        Differentiation   Metastasis       Survival time (months)
  ---------------- ----- ------- ------------------------ ----------------- ---------------- ------------------------
  1                75    IVA     Invasive squamous cell   Poor              Bone             20.8
  2                42    IIIB    Large cell               Poor              Para-aortic ln   84.3
  3                47    IIIB    Large cell               Medium                             89.1
  4                75    IIIB    Large cell               Medium                             81.2
  5                40    IIB     Invasive squamous cell   Medium                             89.1
  6                63    IIB     Invasive squamous cell   Well                               89.4
  7                39    IIB     Large cell               Poor              Lung             47.5
  8                40    IIIB    Large cell               Poor              Multiple organ   57.7
  9                45    IIIB    Large cell               Poor                               45.3
  10               55    IIIB    Large cell               Poor              Para-aortic ln   22.7
  11               74    IIIB    Invasive squamous cell   Poor              Lung             4.5
  12               75    IVA     Large cell               Poor              Multiple organ   33.4
  13               48    IIB     Invasive squamous cell   Medium                             81.7
  14               50    IIB     Invasive squamous cell   Medium                             90.1
  15               57    IIB     Large cell               Poor                               91.7
  16               57    IIIB    Large cell               Poor                               90.3
  17               57    IIIB    Large cell               Poor              Lung             45.1
  18               50    IIB     Invasive squamous cell   Medium                             87.4
  19               68    IIIB    Invasive squamous cell   Poor                               86.3
  20               70    IVA     Large cell               Well                               26.2

**Abbreviation:** ln, lymph node.

###### 

Relative gene expression according to patient age and tumor characteristics

                               *SAG* expression   *Bcl-xL* expression   *Bak* expression   *p73* expression   *p53* expression                                                                                                      
  ---------------------------- ------------------ --------------------- ------------------ ------------------ ------------------ ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
  Age                                                                                                                                                                                                                               
   \<50                        6 (66.7)           3 (33.3)              9 (100)            4 (44.4)           5 (55.6)           9 (100)    4 (44.4)   5 (55.6)   9 (100)    6 (66.7)   3 (33.3)   9 (100)    3 (33.3)   6 (66.7)   9 (100)
   \>51                        6 (54.5)           5 (45.5)              11 (100)           7 (63.6)           4 (36.4)           11 (100)   4 (36.4)   7 (63.6)   11 (100)   4 (36.4)   7 (63.6)   11 (100)   6 (54.5)   5 (45.5)   11 (100)
   Total                       12 (60)            8 (40)                20 (100)           11 (55)            9 (45)             20 (100)   8 (40)     12 (60)    20 (100)   10 (50)    10 (50)    20 (100)   9 (45)     11 (55)    20 (100)
   *P*-value[@b1-ott-7-2161]   0.581                                                       0.390                                            0.714                            0.174                            0.340                 
  Stage                                                                                                                                                                                                                             
   IIB                         3 (42.9)           4 (57.1)              7 (100)            2 (28.6)           5 (71.4)           7 (100)    3 (42.9)   4 (57.1)   7 (100)    2 (28.6)   5 (71.4)   7 (100)    3 (42.9)   4 (57.1)   7 (100)
   IIIB--IVA                   9 (69.2)           4 (30.8)              13 (100)           9 (69.2)           4 (30.2)           13 (100)   5 (38.5)   8 (61.5)   13 (100)   8 (61.5)   5 (38.5)   13 (100)   6 (46.2)   7 (53.8)   13 (100)
   Total                       12 (60)            8 (40)                20 (10)            11 (55)            9 (45)             20 (100)   8 (40)     12 (60)    20 (100)   10 (50)    10 (50)    20 (100)   9 (45)     11 (55)    20 (100)
   *P*-value[@b1-ott-7-2161]   0.252                                                       0.078                                            0.848                            0.155                            0.888                 
  Grade                                                                                                                                                                                                                             
   Poor                        7 (58.3)           5 (41.7)              12 (100)           7 (58.3)           5 (41.7)           12 (100)   3 (25)     9 (75)     12 (100)   7 (58.3)   5 (41.7)   12 (100)   5 (41.7)   7 (58.3)   12 (100)
   Moderate-well               5 (62.5)           3 (37.5)              8 (100)            4 (50)             4 (50)             8 (100)    5 (62.5)   3 (37.5)   8 (100)    3 (37.5)   5 (62.5)   8 (100)    4 (50)     4 (50)     8 (100)
   Total                       12 (60)            8 (40)                200 (100)          11 (55)            9 (45)             20 (100)   8 (40)     12 (60)    20 (100)   10 (50)    10 (50)    20 (100)   9 (45)     11 (55)    20 (100)
   *P*-value[@b1-ott-7-2161]   0.852                                                       0.714                                            0.902                            0.359                            0.714                 
  χ^2^ test[@b1-ott-7-2161]                                                                                                                                                                                                         

**Note:** Expressions were classified with respect to median values for fold changes.

**Abbreviations:** SAG, sensitive to apoptosis gene; Bcl-xL, B-cell lymphoma-extra-large; Bak, Bcl-2 homologous antagonist/killer.

###### 

Correlations between genes according to Spearman analysis

  Spearman's rho             SAG                                                  Bcl-xL                                               Bak                                                p73                                                p53
  -------------------------- ---------------------------------------------------- ---------------------------------------------------- -------------------------------------------------- -------------------------------------------------- --------------------------------------------------
  *SAG*                                                                                                                                                                                                                                      
   Correlation Coefficient   1.000                                                0.752                                                0.589                                              0.400                                              0.368
   *P*-value                 --                                                   \<0.001[\*](#tfn4-ott-7-2161){ref-type="table-fn"}   0.006[\*](#tfn4-ott-7-2161){ref-type="table-fn"}   0.081                                              0.110
  *Bcl-xL*                                                                                                                                                                                                                                   
   Correlation Coefficient   0.752                                                1.000                                                0.550                                              0.389                                              0.417
   *P*-value                 \<0.001[\*](#tfn4-ott-7-2161){ref-type="table-fn"}   --                                                   0.012[\*](#tfn4-ott-7-2161){ref-type="table-fn"}   0.090                                              0.068
  *Bak*                                                                                                                                                                                                                                      
   Correlation Coefficient   0.589                                                0.550                                                1.000                                              0.233                                              0.447
   *P*-value                 0.006[\*](#tfn4-ott-7-2161){ref-type="table-fn"}     0.012[\*](#tfn4-ott-7-2161){ref-type="table-fn"}     --                                                 0.323                                              0.048[\*](#tfn4-ott-7-2161){ref-type="table-fn"}
  *p73*                                                                                                                                                                                                                                      
   Correlation Coefficient   0.400                                                0.389                                                0.233                                              1.000                                              0.562
   *P*-value                 0.081                                                0.090                                                0.323                                              --                                                 0.010[\*](#tfn4-ott-7-2161){ref-type="table-fn"}
  *p53*                                                                                                                                                                                                                                      
   Correlation Coefficient   0.368                                                0.417                                                0.447                                              0.562                                              1.000
   *P*-value                 0.110                                                0.068                                                0.048[\*](#tfn4-ott-7-2161){ref-type="table-fn"}   0.010[\*](#tfn4-ott-7-2161){ref-type="table-fn"}   --

**Note:**

*P*\<0.05 was considered statistically significant.

**Abbreviations:** SAG, sensitive to apoptosis gene; Bcl-xL, B-cell lymphoma-extra-large; Bak, Bcl-2 homologous antagonist/killer.

###### 

Univariate analysis for the relationship between gene expression and survival

  Variables                                             Local-recurrence free survival time (months)   Disease-free survival time (months)   Overall survival time (months)
  ----------------------------------------------------- ---------------------------------------------- ------------------------------------- --------------------------------------------------
  ***SAG***                                                                                                                                  
  High expression (n=8)                                 64 (7.0--77.7)                                 34.5 (2.6--89.1)                      46.4 (4.5--89.1)
  Low expression (n=12)                                 71 (17.4--74.6)                                89.3 (16--91.7)                       89.3 (22.7--91.7)
  *P*-value[a](#tfn6-ott-7-2161){ref-type="table-fn"}   0.278                                          0.213                                 0.026[\*](#tfn7-ott-7-2161){ref-type="table-fn"}
  ***Bcl-xL***                                                                                                                               
  High expression (n=11)                                64 (7--77.7)                                   32.4 (2.6--87.4)                      45.1 (4.5--87.4)
  Low expression (n=9)                                  71.4 (47.5--74.6)                              89.1 (30--91.7)                       89.1 (47.5--91.7)
  *P*-value[a](#tfn6-ott-7-2161){ref-type="table-fn"}   0.114                                          0.056                                 0.002[\*](#tfn7-ott-7-2161){ref-type="table-fn"}
  ***Bak***                                                                                                                                  
  High expression (n=8)                                 72.0 (7.0--74.6)                               84.3 (2.6--91.7)                      84.3 (4.5--91.7)
  Low expression (n=12)                                 65.1 (9.0--77.7)                               47.1 (16--90.0)                       69.7 (20.8--90.3)
  *P*-value[a](#tfn6-ott-7-2161){ref-type="table-fn"}   0.713                                          0.153                                 1.00
  ***p73***                                                                                                                                  
  High expression (n=10)                                65.1 (7.0--72.9)                               40.9 (2.6--89.1)                      52.6 (4.5--89.1)
  Low expression (n=10)                                 70.2 (10.6--77.7)                              86.9 (16--91.7)                       86.9 (22.7--91.7)
  *P*-value[a](#tfn6-ott-7-2161){ref-type="table-fn"}   0.226                                          0.124                                 0.212
  ***p53***                                                                                                                                  
  High expression (n=9)                                 70.5 (7.0--77.7)                               32.4 (2.6--89.4)                      45.3 (4.5--89.4)
  Low expression (n=11)                                 68.9 (17.4--74.6)                              86.3 (16--91.7)                       86.3 (22.7--91.7)
  *P*-value[a](#tfn6-ott-7-2161){ref-type="table-fn"}   0.253                                          0.445                                 0.027[\*](#tfn7-ott-7-2161){ref-type="table-fn"}

**Notes:**

Breslow test.

*P*\<0.05 was considered statistically significant.

**Abbreviations:** SAG, sensitive to apoptosis gene; Bcl-xL, B-cell lymphoma-extra-large; Bak, Bcl-2 homologous antagonist/killer.

###### 

Multivariate analysis for genes predicting overall survival

  Variables              Multivariate analysis Cox regression                   
  ---------------------- -------------------------------------- --------------- -------
  **Overall survival**                                                          
  *SAG*                  0.523                                  0.11--24.11     0.740
  *Bcl-xL*               55.27                                  0.84--3632.75   0.060
  *Bak*                  0.176                                  0.025--1.223    0.079
  *p73*                  2.176                                  0.447--10.61    0.336
  *p53*                  8.53                                   1.34--54.2      0.023

**Note:** Significance of model: *P*=0.011.

**Abbreviations:** SAG, sensitive to apoptosis gene; Bcl-xL, B-cell lymphoma-extra-large; Bak, Bcl-2 homologous antagonist/killer; HR, hazard ratio; CI, confidence interval.
